Menu

Recent Interviews

Gary Cope, President and CEO, Barsele Minerals

Gary Cope
President and CEO | Barsele Minerals
Suite 1130 - 1055 W. Hastings Street, V6E 2E9 Vancouver (CN)

info@barseleminerals.com

+1(604) 687-8566

Interview Barsele Minerals: 'I have never seen a project with such good general conditions'.


Sébastien Plouffe, CEO and Director, Defence Therapeutics

Sébastien Plouffe
CEO and Director | Defence Therapeutics
1680 – 200 Burrard Street, V6C 3L6 Vancouver (CN)

info@defencetherapeutics.com

+1 (514) 947 2272

Interview Defence Therapeutics: Platform strategy the key to success


Humphrey Hale, CEO, Managing Geologist, Carnavale Resources Ltd.

Humphrey Hale
CEO, Managing Geologist | Carnavale Resources Ltd.
Level 2, Suite 9 389 Oxford Street, WA 6016 Mount Hawthorn (AUS)

info@carnavaleresources.com

Interview Carnavale Resources: Good cards for long-term success


21. January 2020 | 13:48 CET

Aphria, Cronos Group, EXMceuticals - it is a buyers' market!

  • Cannabis
Photo credits: pixabay.com

The shares of numerous well-known and unknown cannabis companies have had a dramatic year 2019. Price losses of over 50% are not uncommon. What costs only half today may have become twice as attractive. Due to the large number of cannabis companies listed on the stock exchange, this is the time for investors who are planning a new investment.

time to read: 1 minutes by Mario Hose
ISIN: CA03765K1049 , CA22717L1013 , CA30207T1049


 

Author

Mario Hose

Born and raised in Hannover, Lower Saxony follows social and economic developments around the globe. As a passionate entrepreneur and columnist he explains and compares the most diverse business models as well as markets for interested stock traders.

About the author


Emergence of a market

Among the well-known companies in the cannabis industry are Aphria, Aurora Cannabis, Canopy Growth and also Cronos Group. In the past year new names also came onto the market, but in connection with the price losses of the big players they received little attention or suffered collateral damage.

So it may be more worthwhile than ever to put newcomers like EXMceuticals on the watch list. The cannabis market is in the development phase and in the course of this, changes in legislation around the globe as well as in the product range will be visible.

Education and pioneering work

The large companies such as Aphria and Cronos Group have done a lot of pioneering work in their home country Canada and in many other regions around the globe in recent years. Although the cannabis plant is an ancient remedy, the worldwide wave of legalization has made extensive educational work necessary for politicians, medicine and potential customers.

The confidence in new therapies does not come overnight and it requires a lot of understanding and patience to build a market for a new product universe.

EXMceuticals is building a team of experts

Compared to Aphria and Cronos Group, EXMceuticals is still in a development phase. CEO Jonathan Summers has announced numerous new additions to the team in recent months to develop the operational business with experts who have both experience and an established network.

Although EXMceuticals is headquartered in Canada, due to a shell acquisition, the operational business is located in Europe and Africa.

Entry level at low

Aphria is valued at CAD 1.8 billion market capitalization at a stock market price of CAD 7.02. The shares of Cronos Group changed hands most recently at CAD 11.27 and are valued at CAD 3.9 billion. EXMceuticals is still a lightweight with a market capitalization of 16.5 million CAD at a price of 0.45 CAD, but there is still the opportunity to enter at a low valuation level in order to profit from further developments. As is well known, the profit lies in purchasing.


Author

Mario Hose

Born and raised in Hannover, Lower Saxony follows social and economic developments around the globe. As a passionate entrepreneur and columnist he explains and compares the most diverse business models as well as markets for interested stock traders.

About the author



Conflict of interest & risk note

In accordance with §34b WpHG we would like to point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH may hold long or short positions in the aforementioned companies and that there may therefore be a conflict of interest. Apaton Finance GmbH may have a paid contractual relationship with the company, which is reported on in the context of the Apaton Finance GmbH Internet offer as well as in the social media, on partner sites or in e-mail messages. Further details can be found in our Conflict of Interest & Risk Disclosure.


Related comments:

04. March 2021 | 09:16 CET | by Stefan Feulner

NanoRepro, EXMceuticals, Deutsche Telekom - The profiteers of the new world!

  • Cannabis

The world has changed since last year. The goal is to fight and contain the virus, which has destroyed our everyday life. In addition to the vaccine manufacturers such as BioNTech, AstraZeneca or Moderna, there are more and more new winners emerging from nowhere to become new stock market stars. Currently, the dominant topic, apart from the vaccination programs that are still hardly taking place in Germany, is the "national testing strategy." At the very least, this should enable a more regular and open life. Be there!

Read

07. December 2020 | 10:01 CET | by André Will-Laudien

EXMceuticals, Aurora, Xphyto Therapeutics - Cannabis 2.0 and Psilocybin!

  • Cannabis

The North American Cannabis Index has brought itself back to life in October! The index lost 80% since the beginning of 2019, but it's going up again with the survivors of the industry. Overall, the capitalization of the sector has decreased by 85%, with the election of Joe Biden, the second buying wave of purchases is underway. If hemp production was the initial focus, it is now the applications, the achieved market access and new active ingredient combinations. In the slipstream of the therapeutic plant customer, another topic came to the fore that has caused investors' hearts to stutter in recent weeks: the psychedelic drugs in the form of psilocybin. Psilocybin has been used as an entheogen and hallucinogenic drug since prehistoric times. Now the medical applications are being investigated. The trend is already running at full speed, the Canadian brokerage house Canaccord estimates the market volume of all indications that are suitable for treatment with active psychedelic ingredients to be USD 100 billion.

Read

15. July 2020 | 12:23 CET | by Mario Hose

BioNTech, EXMceuticals, XPhyto - Covid-19 and legalizations offer potential

  • Cannabis

In recent months, the society around the globe has been going through a process of change of deceleration and standstill. Priorities have been redefined and implemented at record speeds in many places. Covid-19 serves as a catalyst for change for many people. The reasons can be different. The development of corona vaccines and antibody tests will make a lot of money in the future and the legalization of cannabis in the USA on a federal level has the potential to create a renaissance.

Read